$VOR News

HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $31 Price Target

We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

HC Wainwright & Co. Maintains Buy on Vor Biopharma, Lowers Price Target to $31

Vor Biopharma: It's A Game Of Wait And See

Vor Biopharma (VOR) Upgraded to Buy: Here's Why

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma shares are trading higher after Wedbush maintained its Neutral rating on the stock and raised its price target from $9 to $15.

Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $15

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

Vor Biopharma Q4 Adj. EPS $(1.63) Beats $(1.64) Estimate

Jefferies Initiates Coverage On Vor Biopharma with Buy Rating, Announces Price Target of $50